GlassScriptPhysician profile
Tiffany Gerber
NPI 1891361440
$7,682.44
in general payments reported to CMS, 2019-2025
23 companies · $2,664 in 2025
The $2,664 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $209 · 2023: $1,837 · 2024: $2,833 · 2025: $2,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,802 · Education: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,802.04 |
| Education | $531.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,439.63 | 2023-2025 | |
| Janssen Biotech, INC. | $1,142.26 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,070.19 | 2023-2025 | Dupixent, Libtayo |
| Ucb, INC. | $641.28 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $591.91 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $564.58 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $299.35 | 2023-2025 | Ilumya, Blu-U, Absorica Ld |
| Incyte Corporation | $293.51 | 2023-2025 | Opzelura |
| Pfizer INC. | $271.92 | 2023-2025 | |
| Lilly USA, LLC | $215.42 | 2022-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $195.71 | 2023-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $183.98 | 2024-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $151.99 | 2023-2024 | |
| Horizon Therapeutics Plc | $122.40 | 2022 | |
| Novo Nordisk INC | $121.12 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $88.72 | 2023-2025 | Otezla, Otezla |
| Organogenesis INC. | $86.40 | 2025 | Puraply Wound Matrix, Cygnus Dual, Novachor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.43 | 2023-2025 | Spevigo |
| Galderma Laboratories, L.P. | $35.51 | 2025 | Nemluvio |
| Fresenius Kabi USA, LLC | $34.37 | 2024 | Idacio |
| Arcutis Biotherapeutics, INC. | $34.09 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.44 | 2021 | |
| Organon LLC | $9.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Gerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.